These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32931923)

  • 1. Automated generation of decision-tree models for the economic assessment of interventions for rare diseases using the RaDiOS ontology.
    Prieto-González D; Castilla-Rodríguez I; González E; Couce ML
    J Biomed Inform; 2020 Oct; 110():103563. PubMed ID: 32931923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards the automated economic assessment of newborn screening for rare diseases.
    Prieto-González D; Castilla-Rodríguez I; González E; Couce ML
    J Biomed Inform; 2019 Jul; 95():103216. PubMed ID: 31128259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Methods and Newborn Screening Assessment.
    Castilla-Rodríguez I; Vallejo-Torres L; Couce ML; Valcárcel-Nazco C; Mar J; Serrano-Aguilar P
    Adv Exp Med Biol; 2017; 1031():267-281. PubMed ID: 29214578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of screening infants at risk of hearing impairment: an international analysis.
    Burke MJ; Shenton RC; Taylor MJ
    Int J Pediatr Otorhinolaryngol; 2012 Feb; 76(2):212-8. PubMed ID: 22129917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
    Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
    PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
    Grosse SD; Thompson JD; Ding Y; Glass M
    Milbank Q; 2016 Jun; 94(2):366-91. PubMed ID: 27265561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of decision analytic modeling in the health economic assessment of spinal intervention.
    Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
    Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
    Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Controversial Issues in Economic Evaluation (III): health Care Interventions in Special Situations].
    Espín Balbino J; Brosa Riestra M; Oliva Moreno J; Trapero-Bertran M;
    Rev Esp Salud Publica; 2015; 89(3):237-47. PubMed ID: 26388338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Economic Decision Tree Models of Diagnostics for Dummies: A Pictorial Primer.
    Rautenberg T; Gerritsen A; Downes M
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32183372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated Cost-effectiveness of Newborn Screening for Congenital Cytomegalovirus Infection in China Using a Markov Model.
    Chen K; Zhong Y; Gu Y; Sharma R; Li M; Zhou J; Wu Y; Gao Y; Qin G
    JAMA Netw Open; 2020 Dec; 3(12):e2023949. PubMed ID: 33275150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.
    Autti-Rämö I; Mäkelä M; Sintonen H; Koskinen H; Laajalahti L; Halila R; Kääriäinen H; Lapatto R; Näntö-Salonen K; Pulkki K; Renlund M; Salo M; Tyni T
    Acta Paediatr; 2005 Aug; 94(8):1126-36. PubMed ID: 16188860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.
    Vemer P; Corro Ramos I; van Voorn GA; Al MJ; Feenstra TL
    Pharmacoeconomics; 2016 Apr; 34(4):349-61. PubMed ID: 26660529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technologies for rare diseases: does conventional HTA still apply?
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):315-7. PubMed ID: 24702042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study.
    Xie Y; Nguyen QD; Hamzah H; Lim G; Bellemo V; Gunasekeran DV; Yip MYT; Qi Lee X; Hsu W; Li Lee M; Tan CS; Tym Wong H; Lamoureux EL; Tan GSW; Wong TY; Finkelstein EA; Ting DSW
    Lancet Digit Health; 2020 May; 2(5):e240-e249. PubMed ID: 33328056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of long-term impacts of universal newborn hearing screening.
    Chiou ST; Lung HL; Chen LS; Yen AM; Fann JC; Chiu SY; Chen HH
    Int J Audiol; 2017 Jan; 56(1):46-52. PubMed ID: 27598544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
    Kent S; Becker F; Feenstra T; Tran-Duy A; Schlackow I; Tew M; Zhang P; Ye W; Lizheng S; Herman W; McEwan P; Schramm W; Gray A; Leal J; Lamotte M; Willis M; Palmer AJ; Clarke P
    Pharmacoeconomics; 2019 Nov; 37(11):1305-1312. PubMed ID: 31347104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency.
    Vallejo-Torres L; Castilla I; Couce ML; Pérez-Cerdá C; Martín-Hernández E; Pineda M; Campistol J; Arrospide A; Morris S; Serrano-Aguilar P
    Pediatrics; 2015 Aug; 136(2):e424-32. PubMed ID: 26169436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.